Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) Director Ping Ji sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $16.63, for a total value of $83,150.00. Following the completion of the sale, the director owned 131,667 shares of the company’s stock, valued at $2,189,622.21. This trade represents a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Adlai Nortye Price Performance
NASDAQ ANL traded down $0.32 on Thursday, hitting $15.43. 66,283 shares of the company traded hands, compared to its average volume of 372,919. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65. The business’s 50 day moving average price is $13.89 and its 200-day moving average price is $11.96. Adlai Nortye Ltd. Sponsored ADR has a 52-week low of $0.88 and a 52-week high of $17.25.
Analyst Ratings Changes
Several research firms recently issued reports on ANL. Wall Street Zen lowered shares of Adlai Nortye from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Oppenheimer assumed coverage on shares of Adlai Nortye in a research report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 price target for the company. Loop Capital set a $49.00 price objective on shares of Adlai Nortye in a research note on Tuesday, September 8th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Adlai Nortye in a research report on Tuesday, September 8th. Finally, Jefferies Financial Group started coverage on shares of Adlai Nortye in a report on Thursday, September 10th. They issued a “buy” rating and a $31.00 target price for the company. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adlai Nortye has an average rating of “Moderate Buy” and an average price target of $29.50.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new position in Adlai Nortye during the second quarter valued at $1,302,000. Braidwell LP bought a new stake in shares of Adlai Nortye in the 2nd quarter worth about $9,145,000. Boone Capital Management LLC purchased a new stake in shares of Adlai Nortye during the 2nd quarter valued at about $2,971,000. ADAR1 Capital Management LLC purchased a new stake in shares of Adlai Nortye during the 1st quarter valued at about $816,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Adlai Nortye in the 1st quarter valued at about $1,140,000. 35.21% of the stock is owned by hedge funds and other institutional investors.
About Adlai Nortye
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.
Adlai Nortye’s lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.
Featured Stories
- Five stocks we like better than Adlai Nortye
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
- Is Palantir Worth $250 or $1? Bulls and Burry Arrive at Opposite Conclusions
- 3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure Builds
- Meta One Subscriptions Show Positive Early Signs, Analysts Forecast Long-Term Growth
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
